Title : The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Pub. Date : 2011 May 1

PMID : 21505103






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The BCR-ABL(T315I) mutant is highly resistant to imatinib, nilotinib, and dasatinib, and is frequently detected in relapsed patients. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens